News: Companies

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors
05:01pV F CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
AQ
05:01pCantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor
AQ
05:01pCantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer
AQ
05:01pCANTARGIA : ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC
AQ
05:01pLinamar Corporation Announces Voting Results from Annual General Meeting
AQ
05:01pMinto Apartment REIT Reports Voting Results from Annual General Meeting of Unitholders
AQ
05:01pForan Announces Voting Results from 2022 AGSM
AQ
05:01pCRESTWOOD EQUITY PARTNERS LP : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05:01pLOYALTY VENTURES INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
05:01pJust Energy Announces Stay Extension and Adjournment of Motions for Meetings Order and Authorization Order
AQ
05:01pDT Midstream Publishes Inaugural Sustainability Report
AQ
05:01pOncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test's Potential to Expand the Clinical Use of Immunotherapy
AQ
05:01pAdvaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
AQ
05:01pKinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
AQ
05:01pFanhua Reports First Quarter 2022 Unaudited Financial Results
AQ
Discover
05:01pIO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022
AQ
05:01pEQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
AQ
05:01pSurface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
05:01pGalane Gold Ltd. Releases Financial and Operating Results for Q1
AQ
05:01pPDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022
AQ
05:01pAlaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting
AQ
05:01pUniversity of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
05:01pNW Natural Water Continues Growth in Washington with Two More Acquisitions
BU
05:01pWestRock Announces Participation in Upcoming Investor Conference
BU
05:01pRubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
GL
05:01pLIZHI INC. Reports First Quarter 2022 Unaudited Financial Results
GL
05:01pReport On Financial Results For The Three Months Ended March 31, 2022
GL
05:01pBeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
BU
05:01pAdagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
GL
05:01pHarpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting
GL
05:01pMerus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
05:01pCue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
05:01pThe New Germany Fund, Inc. Announces Portfolio Manager Change
BU
05:01pGalera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
GL
05:01pZovio Advances Turnaround Plan and Strengthens Financial Position
PR
05:01pHarpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting
GL
05:01pTriNet to Participate at the Stifel 2022 Cross Sector Insight Conference
PR
05:01pSQI Diagnostics Reports Second Quarter 2022 Results
PR
05:01pAdagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
GL
05:01pReport On Financial Results For The Three Months Ended March 31, 2022
GL
05:01pLIZHI INC. Reports First Quarter 2022 Unaudited Financial Results
GL
05:01pRubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
GL
05:01pCue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
05:01pGenmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
BU
05:01pGenmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
05:01pVolatus Aerospace Corp. Announces Record First Quarter Annual Sales
EQ
05:00pBURLINGTON STORES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05:00pMerus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
05:00pSOLID POWER, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05:00pDAYBREAK OIL & GAS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Financial Statements and Exhibits (form 8-K)
AQ
05:00pGalera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
AQ
05:00pHomeStreet Announces Re-election of Board Members and Retirement of Donald Voss as Director, and Appointment of Mark Mason as Chairman, President and Chief Executive Officer and Mark Patterson as Lead Independent Director
BU
05:00pTRANSCRIPT : Autodesk, Inc., Q1 2023 Earnings Call, May 26, 2022
CI
05:00pTRANSCRIPT : The Gap, Inc., Q1 2023 Earnings Call, May 26, 2022
CI
05:00pTRANSCRIPT : StepStone Group Inc., Q4 2022 Earnings Call, May 26, 2022
CI
05:00pTRANSCRIPT : Costco Wholesale Corporation, Q3 2022 Earnings Call, May 26, 2022
CI
05:00pTRANSCRIPT : East West Bancorp, Inc. - Shareholder/Analyst Call
CI
05:00pTRANSCRIPT : Domo, Inc., Q1 2023 Earnings Call, May 26, 2022
CI
05:00pTRANSCRIPT : Lions Gate Entertainment Corp., Q4 2022 Earnings Call, May 26, 2022
CI
05:00pTRANSCRIPT : Red Robin Gourmet Burgers, Inc., Q1 2022 Earnings Call, May 26, 2022
CI
Prev.1  2  3  4   5  6  7  8  9  10Next